[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider",
    "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=885697278df92158aca3b7f787b32a21d201ba951a7751bcb988a09e79cb4eaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765493105,
      "headline": "Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider",
      "id": 137766872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=885697278df92158aca3b7f787b32a21d201ba951a7751bcb988a09e79cb4eaa"
    }
  },
  {
    "ts": null,
    "headline": "Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight",
    "summary": "The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.",
    "url": "https://finnhub.io/api/news?id=6fdd21760a3d9cddf4caa3409f50674a1cbfac444dcdba2abccc6b56310ee9cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765492260,
      "headline": "Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight",
      "id": 137766873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The 67th American Society of Hematology (ASH) Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma treatment from leading biopharmaceutical companies. The conference featured unprecedented efficacy data demonstrating potential functional cures and innovative approaches across novel immunotherapies, bispecific antibodies, and next-generation targeted agents, signaling a major shift in how the disease is managed.",
      "url": "https://finnhub.io/api/news?id=6fdd21760a3d9cddf4caa3409f50674a1cbfac444dcdba2abccc6b56310ee9cd"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta",
    "url": "https://finnhub.io/api/news?id=22f837f5551eb9c63aa7c3b3b2d97d1927fe8bec24dd1b99540870ac46c5821a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765486727,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 137762297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta",
      "url": "https://finnhub.io/api/news?id=22f837f5551eb9c63aa7c3b3b2d97d1927fe8bec24dd1b99540870ac46c5821a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Reliable Cash Flows, Moderate Expectations",
    "summary": "Johnson & Johnson stock nears $200 after rally. Find out why analysts maintain a Hold rating on JNJ stock and a $220 price target.",
    "url": "https://finnhub.io/api/news?id=2be382906dab12ed9de2f07ca1be6fc16436206d351d0a82331034a01a0c2ac1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765479902,
      "headline": "Johnson & Johnson: Reliable Cash Flows, Moderate Expectations",
      "id": 137763027,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1225119943/image_1225119943.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson stock nears $200 after rally. Find out why analysts maintain a Hold rating on JNJ stock and a $220 price target.",
      "url": "https://finnhub.io/api/news?id=2be382906dab12ed9de2f07ca1be6fc16436206d351d0a82331034a01a0c2ac1"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Thursday Afternoon",
    "summary": "Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea",
    "url": "https://finnhub.io/api/news?id=bfcafc9ec8780493ba6315279d6c8f78db8d1f9d67a6d4376a99816c114e8cee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765478729,
      "headline": "Sector Update: Health Care Stocks Rise Thursday Afternoon",
      "id": 137760427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea",
      "url": "https://finnhub.io/api/news?id=bfcafc9ec8780493ba6315279d6c8f78db8d1f9d67a6d4376a99816c114e8cee"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend Stocks to Double Up on Right Now",
    "summary": "After recently coming under pressure, these three dividend stocks have both yield and rebound potential.",
    "url": "https://finnhub.io/api/news?id=af23d27133a895f2bc131d802c0154d5aea495eeaeea93b32d3a8af7010542e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765478100,
      "headline": "3 Dividend Stocks to Double Up on Right Now",
      "id": 137760431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "After recently coming under pressure, these three dividend stocks have both yield and rebound potential.",
      "url": "https://finnhub.io/api/news?id=af23d27133a895f2bc131d802c0154d5aea495eeaeea93b32d3a8af7010542e2"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend ETFs to Buy and Hold for Life if the Market Crashes",
    "summary": "Dividend ETFs may be the best investment you can make today. The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT), iShares Global Consumer Staples ETF (NYSEARCA:KXI), and iShares US Pharmaceuticals ETF (NYSEARCA:IHE) are worth considering first. These ETFs can help you ride through a near-term market crash by providing ballast while providing you with income to ... 3 Dividend ETFs to Buy and Hold for Life if the Market Crashes",
    "url": "https://finnhub.io/api/news?id=65b7244e319433aeca0c55b90652e65a14e45e631d664fc6d650ab14893f2848",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765472801,
      "headline": "3 Dividend ETFs to Buy and Hold for Life if the Market Crashes",
      "id": 137759741,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividend ETFs may be the best investment you can make today. The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT), iShares Global Consumer Staples ETF (NYSEARCA:KXI), and iShares US Pharmaceuticals ETF (NYSEARCA:IHE) are worth considering first. These ETFs can help you ride through a near-term market crash by providing ballast while providing you with income to ... 3 Dividend ETFs to Buy and Hold for Life if the Market Crashes",
      "url": "https://finnhub.io/api/news?id=65b7244e319433aeca0c55b90652e65a14e45e631d664fc6d650ab14893f2848"
    }
  },
  {
    "ts": null,
    "headline": "ASH 2025: J&J’s Tecvayli + Darzale set to redefine early relapse MM",
    "summary": "Tecvayli + Darzalex delivers superior efficacy in early relapsed MM, positioning J&J to dominate the R/R market.",
    "url": "https://finnhub.io/api/news?id=d811c475914e4045ea6092ef8a1ae0dc952824b6343231cb8afc26672226c26b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765470458,
      "headline": "ASH 2025: J&J’s Tecvayli + Darzale set to redefine early relapse MM",
      "id": 137758757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Tecvayli + Darzalex delivers superior efficacy in early relapsed MM, positioning J&J to dominate the R/R market.",
      "url": "https://finnhub.io/api/news?id=d811c475914e4045ea6092ef8a1ae0dc952824b6343231cb8afc26672226c26b"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Broadcom, Exxon Mobil, Johnson & Johnson, Investors Title and Friedman Industries",
    "summary": "AVGO draws attention as analysts spotlight its AI-driven momentum alongside notable updates on XOM, JNJ, ITIC and FRD.",
    "url": "https://finnhub.io/api/news?id=f271256446783e28d5450a03708d65855065d4a44bdd1d18ccd6ab121bb2a793",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765446840,
      "headline": "The Zacks Analyst Blog Highlights Broadcom, Exxon Mobil, Johnson & Johnson, Investors Title and Friedman Industries",
      "id": 137756872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AVGO draws attention as analysts spotlight its AI-driven momentum alongside notable updates on XOM, JNJ, ITIC and FRD.",
      "url": "https://finnhub.io/api/news?id=f271256446783e28d5450a03708d65855065d4a44bdd1d18ccd6ab121bb2a793"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Johnson & Johnson (JNJ) Could Change Following New Multiple Myeloma Breakthrough Data",
    "summary": "Johnson & Johnson recently reported Phase 3 data showing that its TECVAYLI plus DARZALEX FASPRO combination cut the risk of disease progression or death for relapsed or refractory multiple myeloma patients and secured US FDA Breakthrough Therapy Designation, while updated CARVYKTI results pointed to durable, treatment-free remissions with earlier-line use. Together, these oncology data reinforce Johnson & Johnson’s push into next-generation blood cancer therapies, potentially reshaping...",
    "url": "https://finnhub.io/api/news?id=b13588ae92eeb7a23ca404782cf1d9ff5aba909da7bbc9d9296870242646a094",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765440759,
      "headline": "The Bull Case For Johnson & Johnson (JNJ) Could Change Following New Multiple Myeloma Breakthrough Data",
      "id": 137755851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson recently reported Phase 3 data showing that its TECVAYLI plus DARZALEX FASPRO combination cut the risk of disease progression or death for relapsed or refractory multiple myeloma patients and secured US FDA Breakthrough Therapy Designation, while updated CARVYKTI results pointed to durable, treatment-free remissions with earlier-line use. Together, these oncology data reinforce Johnson & Johnson’s push into next-generation blood cancer therapies, potentially reshaping...",
      "url": "https://finnhub.io/api/news?id=b13588ae92eeb7a23ca404782cf1d9ff5aba909da7bbc9d9296870242646a094"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Highlights Growth Potential in Johnson & Johnson (JNJ), Maintains Buy",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Stocks to Buy for the Long Term. On December 5, Guggenheim boosted the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $227 from $206 and maintained a Buy rating on the shares. According to the analyst research note, the update came after the firm […]",
    "url": "https://finnhub.io/api/news?id=2aff5c5a74d0293cad7c1413cfd9b2a95fdd966a7369365fd04efe019d6770e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765439416,
      "headline": "Guggenheim Highlights Growth Potential in Johnson & Johnson (JNJ), Maintains Buy",
      "id": 137755852,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Stocks to Buy for the Long Term. On December 5, Guggenheim boosted the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $227 from $206 and maintained a Buy rating on the shares. According to the analyst research note, the update came after the firm […]",
      "url": "https://finnhub.io/api/news?id=2aff5c5a74d0293cad7c1413cfd9b2a95fdd966a7369365fd04efe019d6770e7"
    }
  },
  {
    "ts": null,
    "headline": "Pharma’s top deals in 2025",
    "summary": "The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.",
    "url": "https://finnhub.io/api/news?id=1688ec05621168c1dcfec999e852f94c942a9065978b871e6a6a61bba8ddcdc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765439215,
      "headline": "Pharma’s top deals in 2025",
      "id": 137756920,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.",
      "url": "https://finnhub.io/api/news?id=1688ec05621168c1dcfec999e852f94c942a9065978b871e6a6a61bba8ddcdc1"
    }
  }
]